FDA panel narrowly backs unapproved peptide drugs favored by RFK Jr.

An FDA panel has narrowly backed unapproved peptide drugs favored by RFK Jr. This decision was reached following reviews at the US Food and Drug Administration headquarters in Silver Spring, Maryland. The panel's narrow support indicates a shift for these specific peptide treatments, which currently remain unapproved. The development is closely linked to the preferences of RFK Jr., marking a pivotal moment for the regulatory status of these drugs as reported on April 28, 2026.